Feb 24, 2026 12:02PM
Jan 21, 2026 12:02PM
Jan 7, 2026 12:03PM
Jan 7, 2026 12:02PM
Dec 15, 2025 12:39PM
Dec 11, 2025 12:29PM
Oct 16, 2025 02:58PM AB Science shares initial phase 1 data for AB8939-venetoclax combination
Oct 16, 2025 02:57PM
Oct 14, 2025 02:36AM
Oct 14, 2025 02:36AM
Oct 10, 2025 12:10PM
Jul 30, 2025 01:45AM
Jul 24, 2025 01:57AM
Jul 24, 2025 01:56AM AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
Jul 4, 2025 02:01AM
Jun 23, 2025 02:03AM
Jun 12, 2025 01:59AM
May 12, 2025 02:14AM
Apr 23, 2025 12:59PM
Jan 29, 2025 01:03PM
Dec 17, 2024 01:04PM AB Science provides a summary of the webcast held on December 16, 2024
Oct 10, 2024 02:27AM
Sep 26, 2024 02:28AM
May 13, 2024 12:08PM
Mar 7, 2024 09:20AM
Jan 15, 2024 12:06PM
Sep 29, 2023 01:49PM
Jun 1, 2023 12:01PM AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
May 17, 2023 02:14PM
May 9, 2023 12:06PM
Apr 28, 2023 12:41PM
Apr 27, 2023 02:41PM
Apr 18, 2023 12:55PM
Mar 13, 2023 01:09PM
Feb 28, 2023 02:03AM AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
Dec 29, 2022 12:08PM
Dec 27, 2022 01:04PM
Nov 21, 2022 12:09PM
Apr 29, 2022 12:33PM
Jan 19, 2022 12:02PM
Nov 22, 2021 12:20PM
Nov 18, 2021 02:40PM AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
Oct 18, 2021 12:14PM
Oct 4, 2021 12:10PM
Sep 22, 2021 12:09PM
Jun 28, 2021 01:59PM
Sep 30, 2020 11:57AM
Apr 30, 2020 03:17PM
Mar 31, 2020 11:35AM AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS), allowing U.S. patient enrollment to commence in Phase 3 study
Mar 9, 2020 04:06PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All